SHOT DOWN: U.S. regulators say that without more data and possibly more patient studies, they can't approve an experimental diabetes pill being developed by Bristol-Myers Squibb and AstraZeneca.
SAFETY CONCERNS: Government advisers last summer said dapagliflozin should not be approved because of risk of breast and bladder cancer, infections and possibly liver damage. The companies say they're committed to the drug.
RIPPLE EFFECT?: Several other companies are testing similar compounds, which likely will be scrutinized to see if they have the same risks.
"OBAMA GO HOME." President Blasted By Pro-Gun Protesters During Roseburg Visit - Bearing Arms - Barack Obama, Umpqua Community College
The Problem Isn't Guns Or White Men | Human Events
Quinnipiac Poll Shows Senate Split in Swing States | RedState
- Vladimir Putin’s Russia Adopts Concealed Carry
The truth about gun deaths: numbers and actual solutions
Obama's answer on Putin leaves us 'literally speechless'
Here's Trey Gowdy's Scathing Letter to Democrat Elijah Cummings